Dimercaprol Clinical Trials

Size	Price	Qty
100mg	USD 147
1g	USD 479

Clinical Trials

Several clinical trials are investigating Dimercaprol across respiratory, infectious, and post-transplantation conditions, including mild allergic and bronchial asthma, COVID-19, multi-site bacterial infections, and post-allogeneic hematopoietic stem cell transplantation lung complications. Supported by academic and federal institutions, including McMaster University, the Fraunhofer-Institute, Mansoura University, Washington University School of Medicine, and the National Institutes of Health, these studies comprise Phase 2, non-applicable, and unassigned phase protocols. Active recruitment for these trials is either currently ongoing or slated to begin shortly.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06317909	Recruiting	Mild Allergic Asthma	Fraunhofer-Institute of Toxicology and Experimental Medicine	2024-06-01	Not Applicable
NCT06381739	Not yet recruiting	COVID-19 Infection	McMaster University\|Canadian Institutes of Health Research (CIHR)	2024-06	Phase 2
NCT06376617	Not yet recruiting	Bronchial Asthma	Mansoura University	2024-04-25	Not Applicable
NCT03482245	Recruiting	Pneumonia\|Necrotizing Soft Tissue Infection\|Intraabdominal Infections\|Infection Joint	Washington University School of Medicine\|National Institute of General Medical Sciences (NIGMS)	2024-04-16	Not Applicable
NCT06093867	Recruiting	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)	National Heart Lung and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	2024-04-08	--

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Dimercaprol product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Dimercaprol acts as an acrolein scavenger that directly inhibits human immunodeficiency virus type 1 (HIV-1) Tat protein activity, thereby suppressing downstream viral transcription, viral particle production, and host cell infectivity. This targeted neutralization of reactive aldehydes and inhibition of viral expression attenuate pathogen-induced cellular damage and inflammatory signaling, providing clinical relevance for treating respiratory and infectious diseases such as asthma, pneumonia, and viral infection.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).